Home > Insider Trading > Filing (0001140361-25-000339)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1124105	Gyre Therapeutics Inc.	GYRE	Pharmaceutical Preparations (2834)	562020050

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1985547	Songjiang Ma	C/O Gyre Therapeutics, Inc. 12770 High Bluff Drive, Suite 150 San Diego CA 92130	President	No	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2025-01-02	2,000	$12.40	2,920,467	No	4	S	Indirect	By Spouse
Common Stock	Disposition	2025-01-03	1,167	$11.03	2,919,300	No	4	S	Indirect	By Spouse
Common Stock	Disposition	2024-01-03	833	$11.85	2,918,467	No	4	S	Indirect	By Spouse

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Indirect	By Spouse
No	4	S	Indirect	By Spouse
No	4	S	Indirect	By Spouse

Footnotes

This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024.
The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $11.99 to $12.80. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $10.73 to $11.70. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $11.73 to $12.27. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.